PPIs Linked to Worse Outcomes With Widely Used Breast Cancer Drug
Using proton pump inhibitors (PPIs) during treatment with palbociclib (Ibrance) was linked to higher risks of progression and death among patients with breast cancer, according to a retrospective cohort study from South Korea. Among over 1,300 women, the median clinical progression-free survival (PFS) in the group taking both a PPI and palbociclib was 25.3 months […]
Wide Variation in CGM Settings for Kids With Diabetes Signals Education Gaps
CHICAGO — Kids using continuous glucose monitors (CGMs) to manage their diabetes often do not have settings in place to alert them and their caregivers about out-of-range sugar levels, suggesting possible gaps in education and onboarding, real-world data showed. In a study that included 150 children and teenagers using CGMs for their type 1 or […]
Possible Role for Ipilimumab in Metastatic Bladder Cancer, Study Suggests
A tailored immunotherapy regimen using nivolumab (Opdivo) induction and “boosts” with nivolumab and high-dose ipilimumab (Yervoy) as second-line treatment for metastatic urothelial cancer was associated with higher response rates compared with historical controls, the phase II TITAN-TCC trial showed. Among 83 patients in the intention-to-treat (ITT) population, a confirmed investigator-assessed objective response occurred in 33% […]
Type 2 Diabetes Patients Can Also Benefit From Fully Closed-Loop System
Even patients with type 2 diabetes can benefit from using a fully closed-loop insulin delivery system, also known as an artificial pancreas, according to an open-label crossover trial. In the randomized trial of 28 adults, patients spent a greater average proportion of time in target glucose range — 70 to 180 mg/dL (3.9 to 10.0 […]
OS Benefit Eludes Second-Line Niraparib Maintenance in Ovarian Cancer
For women with platinum-sensitive recurrent ovarian cancer, maintenance therapy using an individualized starting dose of niraparib (Zejula) did not improve overall survival (OS) despite producing a statistically and clinically significant progression-free survival (PFS) benefit in the phase III NORA study. An interim analysis of the key secondary endpoint showed a median OS of 46.3 months […]
Aortic Aneurysm Score Paves the Way for More Targeted Screening
Efforts to screen for ascending aortic enlargement in the general population may be improved using a new prediction model based on common clinical variables easily gathered from medical records, researchers found. The AORTA clinical score was found to correlate with measured ascending aortic diameters in development from a large U.K. Biobank cohort and externally validation […]
Air Force Mom Faces Advanced Breast Cancer
Defending their country using the most innovative tools and methods available is what the warriors in Melinda’s family have always done. In the 1980s, Melinda was working as an Air Force procurement officer in North Dakota when she met her husband who, like her father, flew B-52 bombers. Spending three years in Germany and relocating […]
Can obesity and stress influence appetite? New study shows it’s all in your head
In a series of experiments using functional magnetic resonance imaging (fMRI) to measure brain activity across networks in the brain, Johns Hopkins Medicine researchers looked at how stress might increase appetite in obese and lean adults. The researchers found that stress impacts the brain’s responses to food, and that both lean and obese adults react […]
Intermittently Scanned CGM Reduced HbA1c in Type 1 Diabetes
Adults with uncontrolled type 1 diabetes saw a benefit when using intermittently scanned continuous glucose monitoring (CGM), the randomized FLASH-UK Trial showed. Compared with traditional fingerstick testing, use of a intermittently scanned CGM, which offers optional alarms for high and low blood glucose levels set by the user, reduced HbA1c levels, with an adjusted mean […]
SGLT2 Inhibitors, GLP-1 RAs Not Cost-Effective as First-Line T2D Agents
Although using newer classes of diabetes drugs as first-line therapy can boost life expectancy, this strategy can be quite pricey, according to a cost-effectiveness study. Compared with traditional first-line metformin, first-line SGLT2 inhibitors cost $43,000 more over a lifetime, and first-line GLP-1 receptor agonists cost $49,000 more, reported Neda Laiteerapong, MD, MS, of the University […]